A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy

British Journal of Cancer

Volumn 76, Issue 11, 1997, Pages 1474-1479

  Shibamoto, Y ^a   Ohshio, G ^a   Hosotani, R ^a   Nishimura, Y ^a   Manabe, T ^a   Imamura, M ^a   Abe, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

2 nitroimidazole; Hypoxic cell sensitizer; Intraoperative radiotherapy; KU 2285; Pancreatic cancer

Indexed keywords

2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; RADIOSENSITIZING AGENT;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG TUMOR LEVEL; HUMAN; INTRAOPERATIVE PERIOD; ORAL DRUG ADMINISTRATION; OSTEOSARCOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0030727814     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.580     Document Type: Article

References (22)

1. Adams GE (1978) Hypoxic cell sensitizers for radiotherapy. Int J Radiat Oncol Biol Phys 4: 135-141
2. Brown JM (1995) Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32: 567-576, 1995. Int J Radiat Oncol Biol Phys 32: 883-885
3. Coleman CN, Wasserman TH, Urtasun RC, Kalsey J, Noll L, Hancock S and Phillips TL (1990) Final report of the Phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. Int J Radiat Oncol Biol Phys 18: 389-393
4. Dische S, Chassagne D, Hope-Stone HF, Dawes PJDK, Roberts JT, Yosef H, Bey P, Horiol JC, Jacobson A, Frankendal B, Gonzales Gonzales D, Nguyen TD, Daly NJ, Le Floch O, Newman H, Vieiro E, Bennett MH, Bichel P, Duvillard P, Cook PA, Everett V and Machin D (1993) A trial of Ro 03-8799 (pimonidazole) in carcinoma of the uterine cervix: an interim report from the Medical Research Council Working Party on advanced carcinoma of the cervix. Radiother Oncol 26: 93-103
5. Halberg FE, Cosmatis D, Gundersnn LL, Noyes RD, Hanks GR, Buswell L, Nagorney DM and Coleman CN (1994) RTOG #89-06: a Phase 1 study to evaluate intraoperative radiation therapy and the hypuxic cell sensitizer etanidazole in locally advanced malignancies. Int J Radiat Oncol Biol Phys 28: 201-206
6. Kagiya T, Nishimoto S, Shibamoto Y, Wang J, Zhou L, He YL, Sasai K, Takahashi M and Ahe M (1989) Importance of tumor affinity of nitroazoles in hypuxic radiosensitization. Int J Radiat Oncol Biol Phys 16: 1033-1037
7. Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD and Rotman M (1996) Results of a Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG protocol 90-20). Int J Radiat Oncol Biol Phys 36: 673-680
8. Lee DJ, Cosmatos D, Marcial VA, Fu KK, Rotman M, Cooper JS, Ortiz HG, Beitler JJ, Abrams RA, Curran WJ, Coleman CN and Wasserman TH (1995) Results of an RTOG Phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherpay alone for locally advanced head and neck carcinomas, Int J Radiat Oncol Biol Phys 32: 567-576
9. Overgaard J (1994) Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6: 509-518
10. Oya N, Shibamoto Y, Sasai K, Sugiyama T and Abe M (1993) In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys 27: 1113-1119
11. Oya N, Shibamoto Y, Sasai K, Shibata T, Murata R, Takagi T, Iwai H, Suzuki T and Abe M (1995) Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys 33: 119-127
12. Sasai K, Nishimoto S, Shimokawa K, Hisanaga Y, Kitakabu Y, Shibamoto Y, Zhou L, Wang J, Takahashi M, Kagiya T and Abe M (1991) A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 20: 1249-1254
13. Sasai K, Shibamoto Y, Manahe T, Baba N, Takahashi M, Sakaguchi M and Abe M (1992) Pharmacokinetics of intratumoral RK-28, a new hypoxic radiosensitizer. Int J Radiat Oncol Biol Phys 24: 959-963
14. Shibamoto Y, Nishimoto S, Shimokawa K, Hisanaga Y, Zhou L, Wang J, Sasai K, Takahashi M, Abe M and Kagiya T (1989) Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys 16: 1045-1048
15. Shibamoto Y, Streffer C, Sasai K, Oya N and Abe M (1992) Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay, Int J Radiat Biol 61: 473-478
16. Shibamoto Y, Takahashi M and Abe M (1996a) A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother Oncol 40: 55-58
17. Shibamoto Y, Manabe T, Ohshio G, Sasai K, Nishimura Y, Imamura M, Takahashi M and Abe M (1996b) High-dose intraoperative radiotherapy for unresectable pancreatic cancer, Int J Radiat Oncol Biol Phys 34: 57-63
18. Shibarnoto Y, Nishimura Y and Abe M (1996c) Intraoperative radiotherapy and hyperthermia for unresectable pancreatic cancer. Hepato-Gastroenterology 43: 326-332
19. Shibata T, Shibamoto Y, Oya N, Sasai K, Murata R, Ishigaki T and Abe M (1994) Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys 29: 587-590
20. Tepper JE, Shipley WU, Warshaw AL, Nardi GL, Wood WC and Orlow EL (1987) The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol 5: 579-584
21. Urtasun RC, Coleman CN, Wasserman TH and Phillips TL (1984) Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward? Int J Radiat Oncol Biol Phys 10: 1691-1696
22. Yamamuro T, Kotoura Y, Kasahara K, Iwasaki R, Takahashi M and Abe M (1991) Limb salvage with intraoperatively irradiated tumor tissues preserved in situ in osteosarcoma. In: Limb Salvage. Major Reconstructions in Oncologic and Nontumoral Conditions, Langlais F and Tomeno B (eds), pp 619-625. Springer: N Verlag: Berlin